SRZN

Surrozen, Inc. [SRZN] Stock Forecast

Q: What is Surrozen, Inc. stock symbol ?

Surrozen, Inc. is a US stock, located in South san francisco of Ca and trading under the symbol SRZN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SRZN Stock Summary

Earnings are expected to rise 300% next year

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($14.06M)

Profit margins (-2.28%) are lower than the previous year (-2.21%)

SRZN has less than 1 year of cash runway

Top 10 Correlated Stocks

SRZN

In the News

11:26 29 Nov 2023 SRZN

Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

09:08 29 Nov 2023 SRZN

5 Top Stocks Likely to Come Up With Earnings Beat

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

09:54 29 Nov 2023 SRZN

New Strong Buy Stocks for April 12th

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

04:30 29 Nov 2023 SRZN

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.

11:00 29 Nov 2023 SRZN

How to Diversify Your Penny Stock Investments

Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:07 29 Nov 2023 SRZN

Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now

High volume penny stocks to watch right now. The post Penny Stocks To Buy?

04:41 29 Nov 2023 SRZN

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.

01:33 29 Nov 2023 SRZN

Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know

Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

08:00 29 Nov 2023 SRZN

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements

08:00 29 Nov 2023 SRZN

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.

SRZN Financial details

Company Rating

Neutral

Market Cap

14.06M

Income

-28.45M

Revenue

12.5M

Book val./share

1.49

Cash/share

1.42

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

08 Nov 2023

P/E

-0.48

Forward P/E

-0.39

PEG

0.09

P/S

1.1

P/B

0.3

P/C

0.32

P/FCF

-0.41

Quick Ratio

6.81

Current Ratio

7.25

Debt / Equity

0.09

LT Debt / Equity

0.03

EPS (TTM)

-0.97

EPS next Y

-1.16

EPS next Q

-0.28

EPS this Y

-62.44%

EPS next Y

19.59%

EPS next 5Y

-63.92%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

9.68%

SMA20

2.33%

SMA50

-12%

SMA100

-29.03%

Inst Own

43.35%

Inst Trans

0.83%

ROA

-53%

ROE

-47%

ROC

-0.81%

Gross Margin

100%

Oper. Margin

-306%

Profit Margin

-228%

Payout

Shs Outstand

30.58M

Shs Float

18.5M

Target Price

52W Range

0.3-1.38

52W High

52W Low

RSI

53.45

Rel Volume

0.18

Avg Volume

90.06K

Volume

15.94K

Perf Week

9.68%

Perf Month

4.1%

Perf Quarter

-30.39%

Perf Half Y

-30.69%

Beta

-0.031

Volatility

0.02%, 0.04%

Prev Close

0.31%

Price

0.4497

Change

-2.87%

SRZN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K
Revenue per share	0	0	0.36
Net income per share	-0.93	-2.13	-0.8
Operating cash flow per share	-0.83	-1.98	-1.27
Free cash flow per share	-0.86	-2.03	-1.29
Cash per share	1.4	4.13	2.18
Book value per share	1.35	4.44	2.19
Tangible book value per share	1.35	4.44	2.19
Share holders equity per share	1.35	4.44	2.19
Interest debt per share	0.27	0.32	0.11
Market cap	354.13M	159M	20.2M
Enterprise value	328.74M	133.7M	1.12M
P/E ratio	-10.85	-3.03	-0.73
Price to sales ratio	0	0	1.62
POCF ratio	-12.17	-3.26	-0.46
PFCF ratio	-11.81	-3.17	-0.45
P/B Ratio	7.49	1.45	0.27
PTB ratio	7.49	1.45	0.27
EV to sales	0	0	0.09
Enterprise value over EBITDA	-10.65	-2.46	-0.03
EV to operating cash flow	-11.3	-2.74	-0.03
EV to free cash flow	-10.97	-2.67	-0.02
Earnings yield	-0.09	-0.33	-1.37
Free cash flow yield	-0.08	-0.31	-2.22
Debt to equity	0.2	0.07	0.07
Debt to assets	0.15	0.06	0.06
Net debt to EBITDA	0.82	0.47	0.43
Current ratio	6.9	7.75	8.35
Interest coverage	0	0	22.68
Income quality	0.89	0.89	1.23
Dividend Yield	0	0	0
Payout ratio	0	0	0
Sales general and administrative to revenue	0	0	1.59
Research and developement to revenue	0	0	2.96
Intangibles to total assets	0	0	0
Capex to operating cash flow	0.03	0.03	0.02
Capex to revenue	0	0	-0.06
Capex to depreciation	-0.45	-0.61	-0.37
Stock based compensation to revenue	0	0	0.36
Graham number	5.32	14.58	6.26
ROIC	-0.49	-0.42	-0.39
Return on tangible assets	-0.53	-0.38	-0.31
Graham Net	0.98	3.01	1.84
Working capital	42.95M	91.62M	71.57M
Tangible asset value	47.29M	109.7M	76M
Net current asset value	35.46M	77.72M	67.87M
Invested capital	0.2	0.07	0.07
Average receivables	0	0	989K
Average payables	0	2.25M	1.69M
Average inventory	0	0	0
Days sales outstanding	0	0	57.76
Days payables outstanding	0	0	0
Days of inventory on hand	0	0	0
Receivables turnover	0	0	6.32
Payables turnover	0	0	0
Inventory turnover	0	0	0
ROE	-0.69	-0.48	-0.36
Capex per share	-0.02	-0.05	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.36	0	0	0
Net income per share	-0.37	0.21	-0.53	-0.31	-0.34
Operating cash flow per share	-0.4	-0.01	-0.47	-0.29	-0.33
Free cash flow per share	-0.41	-0.01	-0.48	-0.29	-0.33
Cash per share	2.24	2.18	2.06	1.78	1.42
Book value per share	2.22	2.19	2.1	1.83	1.49
Tangible book value per share	2.22	2.19	2.1	1.83	1.49
Share holders equity per share	2.22	2.19	2.1	1.83	1.49
Interest debt per share	0.16	0.34	0.16	0.15	0.13
Market cap	70.64M	20.2M	18.04M	16.54M	14.94M
Enterprise value	51.22M	1.12M	-4.69M	-15.43M	-15.07M
P/E ratio	-1.35	0.69	-0.28	-0.44	-0.36
Price to sales ratio	0	1.62	0	0	0
POCF ratio	-4.99	-98.56	-1.27	-1.89	-1.47
PFCF ratio	-4.94	-57.24	-1.25	-1.87	-1.47
P/B Ratio	0.91	0.27	0.29	0.3	0.33
PTB ratio	0.91	0.27	0.29	0.3	0.33
EV to sales	0	0.09	0	0	0
Enterprise value over EBITDA	-3.76	-0.51	0.39	1.58	1.96
EV to operating cash flow	-3.62	-5.45	0.33	1.76	1.49
EV to free cash flow	-3.58	-3.16	0.32	1.75	1.49
Earnings yield	-0.19	0.36	-0.88	-0.57	-0.7
Free cash flow yield	-0.2	-0.02	-0.8	-0.53	-0.68
Debt to equity	0.08	0.07	0.08	0.08	0.09
Debt to assets	0.07	0.06	0.07	0.07	0.07
Net debt to EBITDA	1.43	8.8	1.87	3.27	3.9
Current ratio	9.56	8.35	8.61	8.93	7.25
Interest coverage	28.95	-0.35	49.46	0	0
Income quality	1.06	0.26	0.99	0.93	0.97
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0.42	0	0	0
Research and developement to revenue	0	0.75	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.72	0.02	0.01	0
Capex to revenue	0	-0.01	0	0	0
Capex to depreciation	-0.31	-0.31	-0.65	-0.17	0
Stock based compensation to revenue	0	0.12	0	0	0
Graham number	4.32	3.22	5.02	3.59	3.39
ROIC	-0.15	0.23	-0.22	-0.15	-0.23
Return on tangible assets	-0.14	0.08	-0.21	-0.15	-0.19
Graham Net	1.9	1.84	1.74	1.53	1.2
Working capital	74.07M	71.57M	59.25M	51.13M	41.69M
Tangible asset value	77.49M	76M	63.04M	55.06M	45.53M
Net current asset value	68.78M	67.87M	55.87M	48.64M	39.92M
Invested capital	0.08	0.07	0.08	0.08	0.09
Average receivables	83.5K	1.07M	1.98M	1.98M	1.98M
Average payables	390K	510K	414.5K	178.5K	236.5K
Average inventory	1.69M	1.69M	0	0	0
Days sales outstanding	0	14.24	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	6.32	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.17	0.1	-0.25	-0.17	-0.23
Capex per share	0	0	-0.01	0	0

SRZN Frequently Asked Questions

What is Surrozen, Inc. stock symbol ?

Surrozen, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol SRZN

What is Surrozen, Inc. stock quote today ?

Surrozen, Inc. stock price is $0.4497 today.

Is Surrozen, Inc. stock public?

Yes, Surrozen, Inc. is a publicly traded company.

Something similar

Top by Market Cap

NVD.DE

Company Profile

Volume Average 90.06K
Market Capitalization 14.06M
Employee 74
CEO Mr. Craig C. Parker M.B.A.
Headquarters South San Francisco,CA,US
IPO Date 2021-01-11
Website https://www.surrozen.com

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.